Mutation and expression analyses of the MET and CDKN2A in rhabdomyosarcoma with emphasis on MET overexpression

Genes Chromosomes and Cancer

Volumn 46, Issue 4, 2007, Pages 348-358

  Chen, Yuyan ^a   Takita, Junko ^a   Mizuguchi, Masashi ^a   Tanaka, Kiyoshi ^b   Ida, Kohmei ^a   Koh, Katsuyoshi ^a   Igarashi, Takashi ^a   Hanada, Ryoji ^c   Tanaka, Yukichi ^d   Park, Myoung Ja ^e   Hayashi, Yasuhide ^e  

^a UNIVERSITY OF TOKYO   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^d KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^e Gumna Children S Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENE PRODUCT; MESSENGER RNA; SCATTER FACTOR RECEPTOR;

ARTICLE; CARCINOGENESIS; CDKN2A GENE; CONTROLLED STUDY; EMBRYO; FKHR GENE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE NUMBER; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MET GENE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; P14 ARF GENE; P16 INK4A GENE; PAX3 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; RHABDOMYOSARCOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR CELL LINE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

AGE OF ONSET; CELL LINE, TUMOR; CODON, NONSENSE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; MUTATION, MISSENSE; POINT MUTATION; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; RHABDOMYOSARCOMA;

MUS;

EID: 33947146500     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20416     Document Type: Article

References (54)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925.
2. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. 1995. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376:768-771.
3. Buckingham M, Bajard L, Chang T, Daubas P, Hadchouel J, Meilhac S, Montarras D, Rocancourt D, Relaix F. 2003. The formation of skeletal muscle: From somite to limb. J Anat 202:59-68.
4. Chen Y, Takita J, Hiwatari M, Igarashi T, Hanada R, Kikuchi A. Hongo T, Taki T, Ogasawara M, Shimada A, Hayashi Y. 2006. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 45:583-591.
5. Chen YY, Takita J, Chen YZ, Yang HW, Hanada R, Yamamoto K, Hayashi Y. 2003. Genomic structure and mutational analysis of the human KIF1Bα gene located at 1p36.2 in neuroblastoma. Int J Oncol 23:737-744.
6. Chen YY, Takita J, Tanaka K, Ida K, Koh K, Igarashi T, Hanada R, Kikuchi A, Tanaka Y, Toyoda Y, Hayashi Y. 2005. Aberrations of the CHK2 gene are rare in pediatric solid tumors. Int J Mol Med 16:85-91.
7. Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B, Hays DM, Wharam M, Maurer HM, Intergroup Rhabdomyosarcoma Committee. 1990. Prognosis in children with rhabdomyosarcoma: A report of the intergroup rhabdomyosarcoma studies I and II. J Clin Oncol 8:443-452.
8. Dagher R, Helman L. 1999. Rhabdomyosarcoma: An overview. Oncologist 4:34-44.
9. Dalle JH, Fournier M, Nelken B, Mazingue F, Lai JL, Bauters F, Fenaux P, Quesnel B. 2002. p16(INK4a) immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood 99:2620-2623.
10. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. 1994. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 54:2869-2872.
11. Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA, Comoglio PM. 1992. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7:2549-2553.
12. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. 1995. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 55:1129-1138.
13. Epstein JA, Shapiro DN, Cheng J, Lam PY, Maas RL. 1996. Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA 93:4213-4218.
14. Ferracini R, Di Renzo MF, Scotlandi K, Baldini N, Olivero M, Lollini P, Cremona O, Campanacci M, Comoglio PM. 1995. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10:739-749.
15. Ferracini R, Olivero M, Di Renzo MF, Martano M, De Giovanni C, Nanni P, Basso G, Scotlandi K, Lollini PL, Comoglio PM. 1996. Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene 12:1697-1705.
16. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, III, Emanuel BS, Rovera G, Barr FG. 1993. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5:230-235.
17. Ginsberg JP, Davis RJ, Bennicelli JL, Nauta LE, Barr FG. 1998. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 58:3542-3546.
18. Giordano S, Di Renzo MF, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. 1989. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene 4:1383-1388.
19. Iolascon A, Faienza MF, Coppola B, Rosolen A, Basso G, Della Ragione F, Schettini F. 1996. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer 15:217-222.
20. Jeffers M, Rong S, Woude GF. 1996. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74:505-513.
21. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, III, Johnson BE, Skolnick MH. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
22. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. 2004a. Alveolar rhabdomyosarcomas in conditional Pax3: Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18:2614-2626.
23. Keller C, Hansen MS, Coffin CM, Capecchi MR. 2004b. Pax3: Fkhr interferes with embryonic Pax3 and Pax7 function: Implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 18: 2608-2613.
24. Lagutina I, Conway SJ, Sublett J, Grosveld GC. 2002. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol Cell Biol 22:7204-7216.
25. Lillington DM, Goff LK, Kingston JE, Onadim Z, Price E, Domizio P, Young BD. 2002. High level amplification of N-MYC is not associated with adverse histology or outcome in primary retinoblastoma tumours. Br J Cancer 87:779-782.
26. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, Comoglio PM, Di Renzo MF. 2002. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res 62:7025-7030.
27. Matsumoto K, Nakamura T. 1996. Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 119:591-600.
28. Mekki Y, Catallo R, Bertrand Y, Manel AM, Ffrench P, Baghdassarian N, Duhaut P, Bryon PA, Ffrench M. 1999. Enhanced expression of p16ink4a is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Leukemia 13:181-189.
29. Merlino G, Helman LJ. 1999. Rhabdomyosarcoma-working out the pathways. Oncogene 18:5340-5348.
30. Newton WA, Jr., Gehan EA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Tsokos MG, Shimada H, Harms D, Schmidt D, Ninfo V, Cavazzana AO, Gonzalez-Crussi F, Parham DM, Reiman HM, Asmar L, Beltangady MS, Sachs NE, Triche TJ, Maurer HM. 1995. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-An Intergroup Rhabdomyosarcoma study. Cancer 76:1073-1085.
31. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y. 1995. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86:1269-1275.
32. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC. 1994. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049.
33. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, London WB, Yu AL. 2001. p16/ p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p 16 expression is associated with advanced stage disease. Clin Cancer Res 7:3481-3490.
34. Orlow I, Roy P, Barz A, Canchola R, Song Y, Berwick M. 2001. Validation of denaturing high performance liquid chromatography as a rapid detection method for the identification of human INK4A gene mutations. J Mol Diagn 3:158-163.
35. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY. 1999. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59:307-310.
36. Robertson KD, Jones PA. 1999. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18:3810-3820.
37. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C. 1995. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373:699-702.
38. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68-73.
39. Sharp R, Recio JA, Jhappan C, Otsuka T, Liu S, Yu Y, Liu W, Anver M, Navid F, Helman LJ, DePinho RA, Merlino G. 2002. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 8:1276-1280.
40. Sherr CJ. 2001. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731-737.
41. Shibuya N, Taki T, Mugishima H, Chin M, Tsuchida M, Sako M, Kawa K, Ishii E, Miura I, Yanagisawa M, Hayashi Y. 2001. t(10;11)-acute leukemias with MLL-AF10 and MLL-ABI1 chimeric transcripts: Specific expression patterns of ABIl gene in leukemia and solid tumor cell lines. Genes Chromosomes Cancer 32:1-10.
42. Skapek SX, Rhee J, Spicer DB, Lassar AB. 1995. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267:1022-1024.
43. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. 1993. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123:223-235.
44. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. 2002. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 20:2672-2679.
45. Takeo S, Arai H, Kusano N, Harada T, Furuya T, Kawauchi S, Oga A, Hirano T, Yoshida T, Okita K, Sasaki K. 2001. Examination of oncogene amplification by genomic DNA microarray in hepato-cellular carcinomas: Comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 130:127-132.
46. Takita J, Hayashi Y, Kohno T, Yamaguchi N, Hanada R, Yamamoto K, Yokota J. 1997. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Cancer Res 57:907-912.
47. Takita J, Hayashi Y, Nakajima T, Adachi J, Tanaka T, Yamaguchi N, Ogawa Y, Hanada R, Yamamoto K, Yokota J. 1998. The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene 17:3137-3143.
48. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, Hanada R, Yamamoto K, Hayashi Y, Aburatani H. 2004. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 40:120-132.
49. Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C. 2006. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 66:4742-4749.
50. Trusolino L, Comoglio PM. 2002. Scatter-factor and semaphorin receptors: Cell signalling for invasive growth. Nat Rev Cancer 2:289-300.
51. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. 1996. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 148:225-232.
52. Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N. 1995. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373:702-705.
53. Uno K, Takita J, Yokomori K, Tanaka Y, Ohta S. Shimada H, Gilles FH, Sugita K, Abe S, Sako M, Hashizume K, Hayashi Y. 2002. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors. Genes Chromosomes Cancer 34:33-41.
54. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.